Publications by authors named "P Howarth"
Purpose: Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2-directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) evaluated the safety and clinical activity of Dato-DXd in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy.
View Article and Find Full Text PDFRationale: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.
Objectives: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.
Methods: Data of 421 patients with severe asthma (62% female; mean age 51.
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma (SA) are 2 frequently coexisting conditions that are, in most cases, associated with eosinophilic inflammation. The concurrence of both diseases has a negative synergistic impact on disease severity and patients' health-related quality of life. Thus, a holistic, collaborative management of these patients is a critical unmet need.
View Article and Find Full Text PDFArticle Synopsis
- The MARS study aimed to collect long-term safety and effectiveness data for mepolizumab treatment in patients with eosinophilic granulomatosis with polyangiitis in Japan.
- In the study, conducted over 192 weeks, about 58% of patients experienced adverse events, but none were linked directly to mepolizumab. There were notable improvements in patient symptoms and a decrease in the need for oral glucocorticoids.
- The findings support that mepolizumab is well tolerated and effective for managing this condition, demonstrating an increase in symptom-free patients and decreased steroid dependency.